Join us to learn about RNA-targeting therapeutic approaches using cutting-edge antisense technology. The seminar, led by UC Berkeley Professor of Metabolic Biology Anders Näär, will cover his lab’s discovery of microRNAs as therapeutic targets in a range of diseases, including cardiovascular diseases, morbid obesity, Type 2 diabetes, nonalcoholic steatohepatitis (NASH), dry age-related macular degeneration (dAMD), and Duchenne muscular dystrophy (DMD), and follow with a discussion of their antisense-based targeting of SARS-CoV-2 as a novel inhaled therapeutic approach to the treatment of coronavirus infections. Read more about Näär’s IGI-funded SARS-CoV-2 project here.
Join us for the live event on Zoom. All participants and hosts are required to sign into a Zoom account prior to joining meetings hosted by UC Berkeley.
Anders Näär — Anders Näär is a Professor of Metabolic Biology and Vice Chair in the Department of Nutritional Sciences & Toxicology at the University of California, Berkeley. The Näär Lab studies transcriptional and microRNA regulatory mechanisms controlling metabolic homeostasis to guide novel therapeutic strategies for a range of diseases and disorders.
We strive to make our events accessible and inclusive. The Innovative Genomics Institute Building is ADA compliant, and has a lactation room that visitors can use. For disability accommodation information and requests and/or access to the lactation room, please contact Kristy Nordahl at email@example.com or 510-664-7110.